<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2972</article-id>
         <article-id pub-id-type="publisher-id">2972</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Neurobiology</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Nevrobiologija</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Original scientific article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Izvirni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Nevrobiologija</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Diabetična retinopatija kot subklinično vnetje: Analiza citokinov v steklovini in serumu</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Diabetic retinopathy as a subclinical inflammation: Vitreous and serum cytokine analysis</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Diabetična retinopatija kot subklinično vnetje</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Urbančič</surname>
                  <given-names>Mojca</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Korošec</surname>
                  <given-names>Peter</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Fležar</surname>
                  <given-names>Matjaž</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Globočnik Petrovič</surname>
                  <given-names>Mojca</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Očesna klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Department of Ophthalmology, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff2">
            <aff xml:lang="sl">
               <label>2</label>
               <institution>Univerzitetna Klinika za pljučne bolezni in alergijo Golnik, Golnik, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>2</label>
               <institution>University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Mojca Urbančič, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>6</month>
            <year>2020</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>6</month>
            <year>2020</year>
         </pub-date>
         <volume>89</volume>
         <issue>5–6</issue>
         <fpage>243</fpage>
         <lpage>54</lpage>
         <history>
            <date date-type="received">
               <day>10</day>
               <month>7</month>
               <year>2019</year>
            </date>
            <date date-type="accepted">
               <day>9</day>
               <month>9</month>
               <year>2020</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2020, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2020, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2020</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Izhodišče: Diabetično retinopatijo lahko opredelimo kot kronično subklinično vnetje. Želeli smo ugotoviti razlike v ravneh vnetnih citokinov med steklovino in serumom pri bolnikih s proliferativno diabetično retinopatijo (PDR) in pri kontrolni skupini ter primerjati ravni citokinov v steklovini glede na aktivnost PDR. Boljše poznavanje vnetnega dogajanja v očesu bolnikov s PDR bi lahko prispevalo k razvoju novih načinov zdravljenja teh bolnikov.</p>
            <p>Metode: V raziskavo smo vključili 37 bolnikov (37 oči) s PDR, pri katerih je bila potrebna vitrektomija, ter 20 bolnikov (20 oči) z idiopatskim foramnom makule (FM), ki so predstavljali kontrolno skupino. Glede na pregled pred operacijo in oceno očesnega ozadja med samim posegom smo opredelili aktivnost PDR. V steklovini in serumu smo s citometrično metodo CBA (<italic>angl.</italic> Cytometric Bead Array) analizirali citokine interlevkin 1β (IL-1β), dejavnik tumorske nekroze α (TNF-α), makrofagni vnetni protein 1α (MIP-1α), makrofagni vnetni protein 1β (MIP-1β), monocitni kemotaktični protein 1 (MCP-1), žilni endotelni rastni dejavnik (VEGF), interlevkin 6 (IL-6), interlevkin 8 (IL-8), interlevkin 10 (IL-10) in interlevkin 12 (IL-12).</p>
            <p>Rezultati: Ravni vseh citokinov so se v steklovini pomembno razlikovale od ravni v serumu. Raven MCP-1, VEGF, IL-6, IL-8 v steklovini bolnikov s PDR je bila statistično pomembno višja v primerjavi z ravnijo v steklovini bolnikov v kontrolni skupini, raven MIP-1α, IL-10 in IL-12 v steklovini bolnikov s PDR je bila statistično pomembno nižja v primerjavi z bolniki v kontrolni skupini (p &lt; 0,05). Ravni citokinov v serumu bolnikov s PDR se niso pomembno razlikovale od ravni citokinov pri kontrolni skupini. Bolniki z aktivno PDR so imeli v steklovini višjo raven MCP-1, VEGF, IL-6 in IL-8 kot bolniki z inaktivno PDR, a razlike niso bile statistično značilne.</p>
            <p>Zaključek: Z našo analizo smo potrdili pomembne razlike v ravneh citokinov med steklovino in serumom pri bolnikih s PDR, kar kaže na pomen lokalnega vnetnega dogajanja v očesu pri PDR. Višje ravni MCP-1, VEGF, IL-6 in IL-8 nakazujejo aktivnost PDR.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: Diabetic retinopathy can be defined as chronic subclinical inflammation. The purpose of this study was to investigate levels of inflammatory cytokines in the vitreous and serum of patients with proliferative diabetic retinopathy (PDR) and of control group. In addition, the purpose was to evaluate the levels of cytokines with regard to the activity of PDR. A better understanding of intraocular inflammation in patients with PDR could lead to the development of new treatment options for these patients.</p>
            <p>Methods: 37 patients with PDR (37 eyes) that required vitrectomy were included in the study. Twenty patients with idiopathic macular hole (MH) served as a control group. The activity of PDR was defined based on preoperative examination and intraoperative evaluation of the fundus. Cytometric Bead Array (CBA) method was used for cytokine analysis. Cytokines interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein-1α (MIP-1α), macrophage inflammatory protein-1β (MIP-1β), monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) and interleukin-12 (IL-12) were analysed in vitreous and serum samples.</p>
            <p>Results: Levels of all cytokines in the vitreous differed significantly from levels in the serum. Levels of MCP-1, VEGF, IL-6, IL-8 were significantly higher in the vitreous of patients with PDR in comparison with vitreous levels in the control group. Vitreous levels of MIP-1α, IL-10 and IL-12 in patients with PDR were significantly lower in comparison with the control group (p &lt; 0.05). Serum levels of cytokines were similar in both groups. Patients with active PDR had higher vitreous levels of MCP-1,VEGF, IL-6 and IL-8 in comparison with patients with inactive disease, although the differences were not significant.</p>
            <p>Conclusion: Significant differences in cytokine levels in the vitreous compared to serum levels in patients with PDR indicate the importance of local intraocular inflammation. Higher levels of MCP-1, VEGF, IL-6 and IL-8 might reflect the activity of PDR.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>diabetična retinopatija</kwd>
            <kwd>vnetje</kwd>
            <kwd>citokini</kwd>
            <kwd>VEGF</kwd>
            <kwd>MCP-1</kwd>
            <kwd>IL-6</kwd>
            <kwd>IL-8</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>diabetic retinopathy</kwd>
            <kwd>inflammation</kwd>
            <kwd>cytokines</kwd>
            <kwd>VEGF</kwd>
            <kwd>MCP-1</kwd>
            <kwd>IL-6</kwd>
            <kwd>IL-8</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Diabetična retinopatija (DR) je pozni zaplet sladkorne bolezni in še vedno pomemben vzrok slepote v delovno aktivni populaciji (<xref ref-type="bibr" rid="b1">1</xref>). Prve klinično vidne spremembe na očesnem ozadju so običajno mikroanevrizme. Okvara mrežničnih žil se kaže kot večja prepustnost žilja ter zapore kapilar. Večja prepustnost žilja vodi v nastanek edema mrežnice, v mrežnici pa se pojavijo krvavitve in trdi eksudati. Z napredovanjem ishemije začenjo nastajati neovaskularizacije. Glede na prisotnost neovaskularizacij delimo diabetično retinopatijo v dve stopnji: neproliferativno, ko neovaskularizacij še ni, in proliferativno, ko so že prisotne. Zapleti proliferativne diabetične retinopatije so krvavitve v steklovino in trakcijski odstop mrežnice. Posebej opredelimo tudi stanje centralnega dela mrežnice – makule. Če so prisotne diabetične spremembe v makuli, govorimo o diabetični makulopatiji oziroma diabetičnem makularnem edemu. Stanja, ki resno ogrožajo vid, so zapleti proliferativne diabetične retinoaptije in diabetični makularni edem.</p>
         <p>Biokemični mehanizmi, s katerimi hiperglikemija povzroči spremembe v tkivih, niso v celoti pojasnjeni. Obstaja več teorij, najpomembnejše so teorija aldoza reduktaze, teorija končnih produktov glikacije, teorija reaktivnih kisikovih spojin oziroma oksidativnega stresa, teorija protein kinaze C in teorija vnetja. Čeprav se DR klinično kaže predvsem s spremembami na žilju mrežnice, jo lahko opredelimo tudi kot kronično subklinično vnetje. Vnetje se odslikava s spremembami na molekularni ravni, s spremembami na ravni celic in s funkcionalnimi spremembami, kot sta večja prepustnost žilja in slabša vidna funkcija (<xref ref-type="bibr" rid="b2">2</xref>).</p>
         <p>Citokini so raznovrstna skupina proteinov, ki so ključnega pomena v interakcijah med vnetnimi in drugimi celicami. Posamezne celice lahko sintetizirajo različne citokine. Posamezen citokin lahko vpliva na različne tipe celic, lahko pa tudi različno vpliva na populacijo istih celic. Učinke posameznih citokinov pogosto uravnavajo drugi citokini. Tarčne celice, na katere citokin deluje, so lahko iste celice, ki izločajo citokin, celice v neposredni bližini ali v istem mikrookolju, lahko pa tudi bolj oddaljene celice. Citokine, ki uravnavajo delitev celic, imenujemo rastni dejavniki. Citokine, ki vplivajo na kemotakso celic, imenujemo kemokini.</p>
         <p>Hipoksija in ishemija sprožita večje nastajanje žilnega endotelnega rastnega dejavnika (VEGF) v mrežnici, kar povzroči večjo izraženost adhezijskih molekul in levkostazo. Levkostaza vodi v zaporo žilja in zato dodatno ishemijo, ki sproži dodatno sproščanje vnetnih in angiogenih dejavnikov. Poleg VEGF se poveča sinteza drugih vnetnih citokinov in kemokinov, kot so npr. dejavnik tumorske nekroze α (TNF-α), interlevkin 1β (IL-1β), kemotaktični protein za monocite 1 (MCP-1) in makrofagni vnetni protein (MIP). Zlasti TNF-α in IL-1β naj bi bila ključna za porušenje krvno-mrežnične pregrade in za degeneracijo kapilar mrežnice (<xref ref-type="bibr" rid="b3">3</xref>). Angiogeni dejavniki stimulirajo in modulirajo nastajanje neovaskularizacij, ki so značilne za proliferativno diabetično retinopatijo (PDR). V vnetnem okolju je prisotna večja aktivnost matriksnih metaloproteinaz, ki razgrajujejo zunajcelični matriks (<xref ref-type="bibr" rid="b4">4</xref>) in na ta način omogočijo angiogenezo. Matriksno metaloproteinazo 9 (MMP-9) inducira IL-8, isti encim pa nasprotno tudi aktivira IL-8, ki rekrutira več vnetnih celic, kar ustvarja destruktivno pozitivno povratno zanko (<xref ref-type="bibr" rid="b5">5</xref>).</p>
         <p>V več študijah so v steklovini bolnikov s PDR ugotovili višjo raven VEGF (<xref ref-type="bibr" rid="b5">5</xref>-<xref ref-type="bibr" rid="b12">12</xref>). Raven VEGF je korelirala z aktivnostjo bolezni (<xref ref-type="bibr" rid="b10">10</xref>,<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b13">13</xref>). V steklovini bolnikov s PDR so ugotovili tudi višjo raven MCP-1 (<xref ref-type="bibr" rid="b6">6</xref>-<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b13">13</xref>), IL-6 (<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b9">9</xref>) in IL-8 (<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b9">9</xref>,<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b14">14</xref>). Ravni MCP-1, IL-6 in IL-8 v steklovini bolnikov s PDR so korelirale z ravnijo VEGF (<xref ref-type="bibr" rid="b6">6</xref>). Višja raven IL-6 v steklovini pri bolnikih s PDR je korelirala z aktivnostjo bolezni (<xref ref-type="bibr" rid="b15">15</xref>), višja raven IL-8 pa z ishemijo in slabšo napovedjo izida za vid (<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref>). V nekaterih študijah so v steklovini bolnikov s PDR ugotovili tudi višjo raven IL-1β in TNF-α (<xref ref-type="bibr" rid="b9">9</xref>,<xref ref-type="bibr" rid="b18">18</xref>) ter MIP-1β (<xref ref-type="bibr" rid="b19">19</xref>).</p>
         <p>Tudi v serumu bolnikov s sladkorno boleznijo so ugotovili spremembe v ravni citokinov. Tako pri bolnikih s sladkorno boleznijo tipa 1 kot tipa 2 je višja raven C-reaktivnega proteina (CRP), IL-6 in TNF-α ter zlasti ICAM-1, VCAM-1 in E-selectina povezana z nefropatijo, retinopatijo in srčno-žilnimi boleznimi (<xref ref-type="bibr" rid="b20">20</xref>). Tudi v drugih študijah so v serumu bolnikov s PDR ugotovili višjo raven TNF- α, pa tudi VEGF, MCP-1, IL-1β, IL-6 in IL-8 (<xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b20">20</xref>-<xref ref-type="bibr" rid="b22">22</xref>). Nekatere študije niso pokazale razlik v ravneh citokinov IL-1β, TNF-α, IL-6, IL-10 in IL-12 v serumu bolnikov z DR v primerjavi s kontrolno skupino (<xref ref-type="bibr" rid="b22">22</xref>,<xref ref-type="bibr" rid="b23">23</xref>).</p>
         <p>Z našo analizo smo želeli ugotoviti razlike v ravneh citokinov med steklovino in serumom pri bolnikih s PDR in kontrolno skupino ter primerjati ravni citokinov v steklovini glede na aktivnost PDR. Boljše poznavanje vnetnega dogajanja v očesu bolnikov s PDR bi lahko prispevalo k razvoju novih načinov zdravljenja teh bolnikov.</p>
      </sec>
      <sec id="s2" sec-type="Metode">
         <label>2</label>
         <title>Metode</title>
         <p>V raziskavo smo vključili 37 bolnikov s sladkorno boleznijo tipa 2 (37 oči) s PDR, pri katerih je bila potrebna vitrektomija zaradi trakcijskega odstopa, ter 20 bolnikov (20 oči) z idiopatskim foramnom makule (FM), ki so predstavljali kontrolno skupino.</p>
         <p>Izključitvena merila za skupino bolnikov s PDR so bila: sveža krvavitev v steklovino (manj kot tri mesece), laserska fotokoagulacija v zadnjih treh mesecih, zapleti med in po operaciji, izrazite spremembe v fovei (atrofija, fibroza, trdi eksudati), katarakta ter vrednosti glikiranega hemoglobina (HbA1c) nad 10 %. Izključitveno merilo za kontrolno skupino je bila sladkorna bolezen. Izključitvena merila za obe skupini so bili predhodna vitrektomija, sočasna prisotnost druge očesne bolezni, sistemske vnetne bolezni ali hematološke bolezni.</p>
         <p>Bolniki so bili seznanjeni z namenom in potekom raziskave in so se vanjo vključili prostovoljno. Pred vključitvijo v raziskavo so podali pisno soglasje k sodelovanju. Raziskavo je odobrila Komisija Republike Slovenije za medicinsko etiko (118/12/11). Raziskava je bila opravljena v skladu s Helsinško deklaracijo iz leta 1975 (revizija 1983).</p>
         <p>Popisali smo klinične značilnosti bolnikov (starost, spol, trajanje sladkorne bolezni, vrednost glikiranega hemoglobina, indeks telesne mase, prisotnost zdravljenja z inzulinom, arterijske hipertenzije, hiperlipidemije). Podatke o bolnikovem splošnem zdravstvenem stanju in urejenosti sladkorne bolezni smo pridobili z anamnezo in od bolnikovega splošnega zdravnika ali diabetologa. Vrednost HbA1c, izraženo v odstotkih glikiranega hemoglobina, smo izmerili z analizo venske krvi en dan pred operacijo. HbA1c odslikava povprečno raven glukoze v krvi v zadnjih 6–8 tednih in nam služi za oceno urejenosti sladkorne bolezni. Arterijsko hipertenzijo smo opredelili s sistoličnim tlakom, enakim ali višjim od 140 mm Hg in/ali z diastoličnim tlakom, enakim ali višjim od 85 mm Hg, ali na podlagi podatka, da bolnik jemlje antihipertenzivna zdravila. Hiperlipidemijo smo opredelili na podlagi vrednosti celokupnega holesterola več kot 5 mmol/l in/ali vrednosti trigliceridov več kot 2 mmol/l ali na podlagi podatka, da bolnik jemlje hipolipemična zdravila.</p>
         <p>Vsi bolniki so opravili pred operacijo natančen oftalmološki pregled z določitvijo najboljše korigirane vidne ostrine, pregled na biomikroskopu in pregled očesnega ozadja pri široki zenici. Opravili smo gonioskopijo in izmerili očesni tlak. Pri pregledu očesnega ozadja smo beležili aktivne ali neaktivne neovaskularizacije ter obliterirane mrežnične žile pa tudi morebitne dodatne spremembe v makuli. Spremembe očesnega ozadja smo vrednotili tudi med operacijo. Bolnikom smo slikali očesno ozadje s fundusno kamero in makulo z optično koherenčno tomografijo (OCT).</p>
         <p>Glede na pregled očesnega ozadja pred operacijo in oceno očesnega ozadja med posegom smo opredelili aktivnost PDR. Opredelitev aktivnosti PDR smo povzeli po študiji Aiella s sod.: PDR smo opredelili kot aktivno retinopatijo, če so bile ob pregledu (pred in/ali med operacijo) v fibrovaskularnih membranah vidne prekrvljene žile, ali kot neaktivna (involutivna) retinopatija, če so bile prisotne le fibrozne membrane brez prekrvljenih žil (<xref ref-type="bibr" rid="b11">11</xref>).</p>
         <p>Tik pred operacijo smo odvzeli vzorec venske krvi (dve epruveti) iz komolčne vene. Ob začetku vitrektomije smo odvzeli vzorec nerazredčene steklovine (0,5–1,0 ml). Steklovino smo vsrkali iz centralnega dela steklovinskega prostora z vitrektomom v brizgo, ki smo jo priključili na sistem vitrektoma, preden smo odprli dotok znotrajočesne tekočine (<italic>angl.</italic> balanced salt solution, BSS) po infuzijski cevki v oko.</p>
         <p>Vzorec nerazredčene steklovine, ki smo ga odvzeli ob začetku vitrektomije, in serum smo zamrznili na –80 °C in shranili do analize.</p>
         <p>V steklovini in kontrolnem serumu smo s citometrično metodo CBA (<italic>angl.</italic> Cytometric Bead Array) analizirali citokine interlevkin 1β (IL-1β), dejavnik tumorske nekroze α (TNF-α), makrofagni vnetni protein 1α (MIP-1α), makrofagni vnetni protein 1β (MIP-1β), monocitni kemotaktični protein 1 (MCP-1), žilni endotelni rastni dejavnik (VEGF), interlevkin 6 (IL-6), interlevkin 8 (IL-8), interlevkin 10 (IL-10) in interlevkin 12 (IL-12).</p>
         <p>Statistična analiza. Vrednosti spremenljivk niso bile normalno porazdeljene, zato smo za opis uporabili mediano ter najmanjšo in največjo vrednost. Za oceno razlik med primerjanimi skupinami smo uporabili Wilcoxonov test predznačenih rangov in Mann-Whitneyjev test. Za oceno korelacije med skupinami spremenljivk smo uporabili Spearmanov korelacijski koeficient. Zaradi večjega števila testov smo pri oceni statistične pomembnosti uporabili Benjamini-Hochbergovo prilagojeno vrednost p. Kot statistično pomembno smo upoštevali vrednost p, manjšo od 0,05. Statistično analizo smo opravili z računalniškim programom SPSS, verzija 19 (SPSS Inc., Illinois).</p>
      </sec>
      <sec id="s3" sec-type="Rezultati">
         <label>3</label>
         <title>Rezultati</title>
         <p>Raven citokinov smo določali v vzorcih steklovine in seruma 37 bolnikov s PDR ter 20 bolnikov kontrolne skupine (FM). Klinične značilnosti bolnikov so prikazane v <xref ref-type="table" rid="table1">Tabeli 1</xref>.</p>
         <table-wrap position="anchor" id="table1">
            <label>Tabela 1:</label>
            <caption>
               <p> Klinične značilnosti bolnikov s PDR (n = 37) in kontrolne skupine s foramnom makule (FM) (n = 20).</p>
            </caption>
            <table>
               <colgroup>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
               </colgroup>
               <thead>
                  <tr>
                     <th/>
                     <th>PDR (n = 37)</th>
                     <th>FM (n = 20)</th>
                     <th>Vrednost p</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Starost (leta)</td>
                     <td align="right">62,5 ± 11,5</td>
                     <td align="right">71,2 ± 10,2</td>
                     <td align="right">0,009</td>
                  </tr>
                  <tr>
                     <td>Spol</td>
                     <td>
                        <p>19 moških (51,4 %),</p>
                        <p>18 žensk (48,6 %)</p>
                     </td>
                     <td>
                        <p>8 moških (40,0 %),</p>
                        <p>12 žensk (60,0 %)</p>
                     </td>
                     <td align="right">0,32</td>
                  </tr>
                  <tr>
                     <td>Trajanje SB (leta)</td>
                     <td align="right">13,8 ± 8,8</td>
                     <td align="right">0</td>
                     <td/>
                  </tr>
                  <tr>
                     <td>HbA1c (%)</td>
                     <td align="right">7,9 ± 1,0</td>
                     <td align="right">0</td>
                     <td/>
                  </tr>
                  <tr>
                     <td>Zdravljenje z inzulinom (n)</td>
                     <td align="right">16 (70,3 %)</td>
                     <td align="right">0</td>
                     <td/>
                  </tr>
                  <tr>
                     <td>Incidenca arterijske hipertenzije (n)</td>
                     <td align="right">35 (94,6 %)</td>
                     <td align="right">7 (31,8 %)</td>
                     <td align="right">0,0001</td>
                  </tr>
                  <tr>
                     <td>Incidenca hiperlipidemije (n)</td>
                     <td align="right">21 (56,7 %)</td>
                     <td align="right">6 (27,3 %)</td>
                     <td align="right">0,0001</td>
                  </tr>
                  <tr>
                     <td>BMI</td>
                     <td align="right">30,7 ± 4,8</td>
                     <td align="right">24,0 ± 6,3</td>
                     <td align="right">0,0001</td>
                  </tr>
                  <tr>
                     <td>NV šarenice/zakotja (n)</td>
                     <td align="right">2 (5,4 %)</td>
                     <td align="right">0</td>
                     <td/>
                  </tr>
                  <tr>
                     <td>Aktivnost PDR</td>
                     <td>
                        <p>27 aktivna (72,9 %),</p>
                        <p>10 neaktivna (27,1 %)</p>
                     </td>
                     <td align="right">0</td>
                     <td/>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Legenda: PDR – bolniki s proliferativno diabetično retinopatijo; FM – bolniki z idiopatskim foramnom makule; SB – sladkorna bolezen; HbA1c – glikirani hemoglobin; BMI – indeks telesne mase; NV – neovaskularizacija</p>
            </table-wrap-foot>
         </table-wrap>
         <p>Raven citokinov v steklovini smo pri bolnikih s PDR primerjali z ravnijo citokinov v serumu (<xref ref-type="table" rid="table2">Tabela 2</xref>). Ravni vseh analiziranih citokinov so bile v steklovini statistično pomembno različne od ravni v serumu, najbolj pa so izstopale razlike v ravni MCP-1, VEGF, IL-6, IL-8 (p = 0,0025; višja raven v steklovini kot v serumu) ter IL-12 (p = 0,0025; nižja raven v steklovini kot v serumu).</p>
         <table-wrap position="anchor" id="table2">
            <label>Tabela 2:</label>
            <caption>
               <p> Primerjava vzorcev steklovine in seruma bolnikov s PDR (mediana, najmanjša vrednost – največja vrednost; Wilcoxonov test predznačenih rangov).</p>
            </caption>
            <table>
               <colgroup>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
               </colgroup>
               <thead>
                  <tr>
                     <th/>
                     <th align="center" colspan="3">Bolniki s PDR (n = 37)</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <th/>
                     <th>steklovina</th>
                     <th>serum</th>
                     <th>p- vrednost <break/>(Benjamini-Hochberg)</th>
                  </tr>
                  <tr>
                     <td>IL-1β (pg/ml)</td>
                     <td align="right">9,15 (7,51–67,36)</td>
                     <td align="right">7,54 (6,91–15,16)</td>
                     <td align="right">0,0025</td>
                  </tr>
                  <tr>
                     <td>TNF-α (pg/ml)</td>
                     <td align="right">13,4 (2,41–69,09)</td>
                     <td align="right">5,67 (0–23,35)</td>
                     <td align="right">0,008</td>
                  </tr>
                  <tr>
                     <td>MIP-1β (pg/ml)</td>
                     <td align="right">12,09 (2,9–38,02)</td>
                     <td align="right">18,9 (6,89–48,83)</td>
                     <td align="right">0,0056</td>
                  </tr>
                  <tr>
                     <td>IL-12 (pg/ml)</td>
                     <td align="right">3,17 (0–22,26)</td>
                     <td align="right">17,7 (2,49–42,91)</td>
                     <td align="right">0,0002</td>
                  </tr>
                  <tr>
                     <td>MCP-1 (pg/ml)</td>
                     <td align="right">1404,75 (403,05–3990,74)</td>
                     <td align="right">72,6 (25,06–227,83)</td>
                     <td align="right">0,0002</td>
                  </tr>
                  <tr>
                     <td>MIP-1α (pg/ml)</td>
                     <td align="right">9,55 (0–82,83)</td>
                     <td align="right">14,36 (7,78–91,74)</td>
                     <td align="right">0,0014</td>
                  </tr>
                  <tr>
                     <td>IL-8 (pg/ml)</td>
                     <td align="right">93,29 (20,04–295,71)</td>
                     <td align="right">12,08 (10,12–31,69)</td>
                     <td align="right">0,0002</td>
                  </tr>
                  <tr>
                     <td>VEGF (pg/ml)</td>
                     <td align="right">334,96 (26,41–1439,3)</td>
                     <td align="right">39,74 (6,17–149,12)</td>
                     <td align="right">0,0002</td>
                  </tr>
                  <tr>
                     <td>IL-6 (pg/ml)</td>
                     <td align="right">60,82 (13,64–798,23)</td>
                     <td align="right">5,95 (2,41–24,76)</td>
                     <td align="right">0,0002</td>
                  </tr>
                  <tr>
                     <td>IL-10 (pg/ml)</td>
                     <td align="right">5,67 (0–8,12)</td>
                     <td align="right">7,64 (5,3–15,28)</td>
                     <td align="right">0,0014</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Legenda: PDR – proliferativna diabetična retinopatija; IL-1β – interlevkin 1β; TNF-α – dejavnik tumorske nekroze α; MIP-1β – makrofagni vnetni protein 1β; IL-12 – interlevkin 12; MCP-1 – monocitni kemotaktični protein 1; MIP-1α – makrofagni vnetni protein 1α; IL-8 – interlevkin 8; VEGF – žilni endotelni rastni dejavnik; IL-6 – interlevkin 6; IL-10 – interlevkin 10.</p>
            </table-wrap-foot>
         </table-wrap>
         <p>Raven MIP-1α je bila v 16 vzorcih steklovine bolnikov s PDR nižja od minimalne zaznavne koncentracije (&lt; 7 pg / ml), prav tako raven IL-12 v enem vzorcu (&lt; 1 pg/ml) in IL-10 v dveh vzorcih (&lt; 5 pg/ml). V enem vzorcu seruma bolnika s PDR je bila raven TNF-α nižja od minimalne zaznavne koncentracije (&lt; 3 pg/ml). Pri dveh bolnikih kontrolne skupine je bila raven MIP-1β v steklovini pod zaznavno mejo 1 pg/ml.</p>
         <p>Primerjavo vzorcev bolnikov s PDR z vzorci bolnikov s FM prikazuje <xref ref-type="table" rid="table3">Tabela 3</xref>. Vzorci steklovine se glede na raven IL-1β, TNF-α in MIP-1β niso pomembno razlikovali, statistično pomembne razlike pa so bile v ravneh drugih citokinov, pri čemer je najbolj izstopala razlika v ravni VEGF, MCP-1, IL-6 in IL-8 (p = 0,00025). V vzorcih serumov med skupinama nismo ugotovili pomembne razlike v ravni citokinov.</p>
         <p>Raven MCP-1 v steklovini bolnikov s PDR je dobro korelirala z ravnijo IL-6 v steklovini (Spearmanov koeficient 0,65; p = 0,0001) ter z ravnijo IL-8 (Spearmanov koeficient 0,51; p = 0,002). Zmerno korelacijo smo ugotovili tudi med ravnijo VEGF in IL-8 (Spearmanov koeficient 0,43; p = 0,01), med TNFα in IL-10 (Spearmanov koeficient 0,42; p = 0,014), med IL-6 in MIP-1β (Spearmanov koeficient 0,40; p = 0,02), med MIP-1α in IL-10 (Spearmanov koeficient 0,36; p = 0,04), med IL-6 in IL-10 (Spearmanov koeficient 0,35; p = 0,04), med IL-12 in IL-10 (Spearmanov koeficient 0,35; p = 0,042) ter med IL-8 in TNF-α (Spearmanov koeficient 0,35; p = 0,045).</p>
         <table-wrap position="anchor" id="table3">
            <label>Tabela 3:</label>
            <caption>
               <p> Primerjava vzorcev skupine PDR z vzorci kontrolne skupine s foramnom makule (FM) (mediana, najmanjša vrednost – največja vrednost; Mann-Whitneyjev test).</p>
            </caption>
            <table>
               <colgroup>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
               </colgroup>
               <thead>
                  <tr>
                     <th/>
                     <th align="center" colspan="3">Steklovina</th>
                     <th align="center" colspan="3">Serum</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <th/>
                     <th>PDR (n = 37)</th>
                     <th>FM (n = 20)</th>
                     <th>p-vrednost (Benjamini-Hochberg)</th>
                     <th>PDR (n = 37)</th>
                     <th>FM (n = 20)</th>
                     <th>p-vrednost (Benjamini- Hochberg)</th>
                  </tr>
                  <tr>
                     <td>IL-1β (pg/ml)</td>
                     <td>
                        <p>9,15</p>
                        <p>(7,51–67,36)</p>
                     </td>
                     <td>
                        <p>10,5</p>
                        <p>(7,7–35,99)</p>
                     </td>
                     <td align="right">0,53</td>
                     <td>
                        <p>7,54</p>
                        <p>(6,91–15,16)</p>
                     </td>
                     <td>
                        <p>7,72</p>
                        <p>(5,55–15,55)</p>
                     </td>
                     <td align="right">0,89</td>
                  </tr>
                  <tr>
                     <td>TNF-α (pg/ml)</td>
                     <td>
                        <p>13,4</p>
                        <p>(2,41–69,09)</p>
                     </td>
                     <td>
                        <p>21,5</p>
                        <p>(5,16–38,4)</p>
                     </td>
                     <td align="right">0,29</td>
                     <td>
                        <p>5,67</p>
                        <p>(0–23,35)</p>
                     </td>
                     <td>
                        <p>4,79</p>
                        <p>(4,0–8,76)</p>
                     </td>
                     <td align="right">0,79</td>
                  </tr>
                  <tr>
                     <td>MIP-1β (pg/ml)</td>
                     <td>
                        <p>12,09</p>
                        <p>(2,9–38,02)</p>
                     </td>
                     <td>
                        <p>13,44</p>
                        <p>(0–14,4)</p>
                     </td>
                     <td align="right">0,31</td>
                     <td>
                        <p>18,9</p>
                        <p>(6,89–48,83)</p>
                     </td>
                     <td>
                        <p>17,72</p>
                        <p>(10,5–27,72)</p>
                     </td>
                     <td align="right">0,60</td>
                  </tr>
                  <tr>
                     <td>IL-12 (pg/ml)</td>
                     <td>
                        <p>3,17</p>
                        <p>(0–22,26)</p>
                     </td>
                     <td>
                        <p>3,99</p>
                        <p>(2,56–11,18)</p>
                     </td>
                     <td align="right">0,04</td>
                     <td>
                        <p>17,7</p>
                        <p>(2,49–42,91)</p>
                     </td>
                     <td>
                        <p>11,71</p>
                        <p>(7,09–18,84)</p>
                     </td>
                     <td align="right">0,71</td>
                  </tr>
                  <tr>
                     <td>MCP-1 (pg/ml)</td>
                     <td>
                        <p>1404,75</p>
                        <p>(403,05–3990,74)</p>
                     </td>
                     <td>
                        <p>374,17</p>
                        <p>(295,01–881,87)</p>
                     </td>
                     <td align="right">0,00025</td>
                     <td>
                        <p>72,6</p>
                        <p>(25,06–227,83)</p>
                     </td>
                     <td>
                        <p>43,4</p>
                        <p>(30,24–76,64)</p>
                     </td>
                     <td align="right">0,10</td>
                  </tr>
                  <tr>
                     <td>MIP-1α (pg/ml)</td>
                     <td>
                        <p>9,55</p>
                        <p>(0–82,83)</p>
                     </td>
                     <td>
                        <p>14,25</p>
                        <p>(9,67–47,34)</p>
                     </td>
                     <td align="right">0,014</td>
                     <td>
                        <p>14,36</p>
                        <p>(7,78–91,74)</p>
                     </td>
                     <td>
                        <p>20,38</p>
                        <p>(11,83–91,07)</p>
                     </td>
                     <td align="right">0,52</td>
                  </tr>
                  <tr>
                     <td>IL-8 (pg/ml)</td>
                     <td>
                        <p>93,29</p>
                        <p>(20,04–295,71)</p>
                     </td>
                     <td>
                        <p>14,49</p>
                        <p>(13,12–16,64)</p>
                     </td>
                     <td align="right">0,00025</td>
                     <td>
                        <p>12,08</p>
                        <p>(10,12–31,69)</p>
                     </td>
                     <td>
                        <p>12,71</p>
                        <p>(11,21–13,33)</p>
                     </td>
                     <td align="right">0,80</td>
                  </tr>
                  <tr>
                     <td>VEGF (pg/ml)</td>
                     <td>
                        <p>334,96</p>
                        <p>(26,41–1439,3)</p>
                     </td>
                     <td>
                        <p>4,58</p>
                        <p>(3,5–31,79)</p>
                     </td>
                     <td align="right">0,00025</td>
                     <td>
                        <p>39,74</p>
                        <p>(6,17–149,12)</p>
                     </td>
                     <td>
                        <p>25,73</p>
                        <p>(17,62–63,61)</p>
                     </td>
                     <td align="right">0,78</td>
                  </tr>
                  <tr>
                     <td>IL-6 (pg/ml)</td>
                     <td>
                        <p>60,82</p>
                        <p>(13,64–798,23)</p>
                     </td>
                     <td>
                        <p>6,0</p>
                        <p>(5,28–8,1)</p>
                     </td>
                     <td align="right">0,00025</td>
                     <td>
                        <p>5,95</p>
                        <p>(2,41–24,76)</p>
                     </td>
                     <td>
                        <p>9,14</p>
                        <p>(5,81–28,4)</p>
                     </td>
                     <td align="right">0,60</td>
                  </tr>
                  <tr>
                     <td>IL-10 (pg/ml)</td>
                     <td>
                        <p>5,67</p>
                        <p>(0–8,12)</p>
                     </td>
                     <td>
                        <p>6,05</p>
                        <p>(5,84–6,08)</p>
                     </td>
                     <td align="right">0,04</td>
                     <td>
                        <p>7,64</p>
                        <p>(5,3–15,28)</p>
                     </td>
                     <td>
                        <p>6,63</p>
                        <p>(5,43–8,43)</p>
                     </td>
                     <td align="right">0,60</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Legenda: PDR – skupina bolnikov s PDR; FM – skupina bolnikov s foramnom makule; IL-1β – interlevkin 1β; TNF-α – dejavnik tumorske nekroze α; MIP-1β – makrofagni vnetni protein 1β; IL-12 – interlevkin 12; MCP-1 – monocitni kemotaktični protein 1; MIP-1α – makrofagni vnetni protein 1α; IL-8 – interlevkin 8; VEGF – žilni endotelni rastni dejavnik; IL-6 – interlevkin 6; IL-10 – interlevkin 10.</p>
            </table-wrap-foot>
         </table-wrap>
         <p>Primerjavo vzorcev steklovine bolnikov s PDR (n = 37) z aktivno in neaktivno obliko PDR prikazuje <xref ref-type="table" rid="table4">Tabela 4</xref>. Aktivno bolezen je imelo 27 bolnikov s PDR, neaktivno obliko PDR pa 10 bolnikov. Bolniki z aktivno PDR so imeli v steklovini višje ravni MCP-1, VEGF, IL-8 in IL-6, toda razlike niso bile statistično značilne.</p>
         <table-wrap position="anchor" id="table4">
            <label>Tabela 4:</label>
            <caption>
               <p> Primerjava vzorcev steklovine bolnikov s PDR z aktivno in neaktivno obliko PDR (mediana, najmanjša vrednost – največja vrednost; Mann-Whitneyjev test).</p>
            </caption>
            <table>
               <colgroup>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
               </colgroup>
               <thead>
                  <tr>
                     <th/>
                     <th colspan="3">PDR (n = 37)</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <th/>
                     <th>aktivna PDR (n = 27)</th>
                     <th>neaktivna PDR (n = 10)</th>
                     <th>p-vrednost<break/>(Benjamini-Hochberg)</th>
                  </tr>
                  <tr>
                     <td>IL-1β (pg/ml)</td>
                     <td align="right">8,07 (7,51–67,36)</td>
                     <td align="right">28,14 (7,71–56,44)</td>
                     <td align="right">0,41</td>
                  </tr>
                  <tr>
                     <td>TNF-α (pg/ml)</td>
                     <td align="right">13,41 (2,41–69,09)</td>
                     <td align="right">19,58 (3,51–31,52)</td>
                     <td align="right">0,64</td>
                  </tr>
                  <tr>
                     <td>MIP-1β (pg/ml)</td>
                     <td align="right">11,85 (2,9–30,67)</td>
                     <td align="right">16,36 (4,56–38,02)</td>
                     <td align="right">0,32</td>
                  </tr>
                  <tr>
                     <td>IL-12 (pg/ml)</td>
                     <td align="right">2,66 (0–14,99)</td>
                     <td align="right">3,80 (1,07–22,26)</td>
                     <td align="right">0,41</td>
                  </tr>
                  <tr>
                     <td>MCP-1 (pg/ml)</td>
                     <td align="right">1623,19 (437,43–3990,74)</td>
                     <td align="right">987,23 (403,05–1625,84)</td>
                     <td align="right">0,06</td>
                  </tr>
                  <tr>
                     <td>MIP-1α (pg/ml)</td>
                     <td align="right">0 (0–68,26)</td>
                     <td align="right">12,58 (0–82,83)</td>
                     <td align="right">0,48</td>
                  </tr>
                  <tr>
                     <td>IL-8 (pg/ml)</td>
                     <td align="right">112,76 (37,57–295,71)</td>
                     <td align="right">54,97 (20,04–275,07)</td>
                     <td align="right">0,225</td>
                  </tr>
                  <tr>
                     <td>VEGF (pg/ml)</td>
                     <td align="right">477,87 (26,41–1439,30)</td>
                     <td align="right">188,32 (29,86–1367,13)</td>
                     <td align="right">0,20</td>
                  </tr>
                  <tr>
                     <td>IL-6 (pg/ml)</td>
                     <td align="right">62,95 (20,41–798,23)</td>
                     <td align="right">32,82 (13,64–220,31)</td>
                     <td align="right">0,42</td>
                  </tr>
                  <tr>
                     <td>IL-10 (pg/ml)</td>
                     <td align="right">5,57 (0–6,9)</td>
                     <td align="right">5,79 (5,37–8,12)</td>
                     <td align="right">0,26</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Legenda: PDR – vzorci steklovine bolnikov s PDR; IL-1β – interlevkin 1β; TNF-α - dejavnik tumorske nekroze α; MIP-1β – makrofagni vnetni protein 1β; IL-12 – interlevkin 12; MCP-1 – monocitni kemotaktični protein 1; MIP-1α – makrofagni vnetni protein 1α; IL-8 – interlevkin 8; VEGF – žilni endotelni rastni dejavnik; IL-6 – interlevkin 6; IL-10 – interlevkin 10.</p>
            </table-wrap-foot>
         </table-wrap>
      </sec>
      <sec id="s4" sec-type="Razpravljanje">
         <label>4</label>
         <title>Razpravljanje</title>
         <p>Bolniki s PDR so imeli v steklovini pomembno različne ravni vseh določenih citokinov v primerjavi s serumom. Bolniki s PDR so imeli v steklovini pomembno različne ravni citokinov IL-12, MCP-1, MIP-1α, IL-8, VEGF, IL-6 in IL-10 v primerjavi z bolniki kontrolne skupine. Bolniki z aktivno PDR so imeli v steklovini višje ravni MCP-1,VEGF, IL-8 in IL-6 v primerjavi z bolniki z neaktivno PDR, čeprav razlike niso bile statistično značilne. Bolniki s PDR in kontrolna skupina so imeli podobne ravni citokinov v serumu.</p>
         <p>Citokini igrajo pomembno vlogo pri aktiviranju levkocitov, ojačanju in širitvi lokalnega vnetja ter v moduliranju celične proliferacije in razvoju neovaskularizacije. Izvora citokinov v steklovini ne moremo natančno določiti. Prav gotovo jih tvorijo celice mrežnice kot odgovor na vnetje, vendar citokini lahko prehajajo v steklovino tudi iz krvi prek porušene krvno-mrežnične pregrade. Tvorijo jih tudi vnetne celice v steklovini. Ne glede na svoj izvor citokini vplivajo na razvoj DR neposredno in posredno, na podlagi ravni citokinov v steklovini pa lahko posredno sklepamo na dogajanje v mrežnici.</p>
         <p>V steklovini bolnikov s PDR smo ugotovili višjo raven MCP-1, IL-8, VEGF, IL-6, IL-1β in TNF-α, kot v serumu.</p>
         <p>MCP-1 je najpogostejši kemokin in pomemben dejavnik v patogenezi vnetnih sprememb v mrežnici pri DR. Igra pomembno vlogo pri kemotaksi, sproži angiogenezo in fibrozo (<xref ref-type="bibr" rid="b24">24</xref>). Pri bolnikih s PDR so ugotovili višjo raven MCP-1 v steklovini v primerjavi s kontrolno skupino, raven v steklovini pa je bila tudi pomembno višja kot v serumu in je korelirala z aktivnostjo PDR (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b19">19</xref>). Naši rezultati se ujemajo z ugotovitvami omenjenih študij.</p>
         <p>Yoshimura s sod. je ugotovil pomembno višjo raven IL-6, IL-8 in MCP-1 v steklovini bolnikov s PDR in DME in pomembno višjo raven VEGF v steklovini bolnikov s PDR (<xref ref-type="bibr" rid="b6">6</xref>). Več drugih študij je prav tako ugotovilo višjo raven IL-6 in IL-8 v steklovini bolnikov s PDR (<xref ref-type="bibr" rid="b9">9</xref>,<xref ref-type="bibr" rid="b17">17</xref>,<xref ref-type="bibr" rid="b19">19</xref>). Naši rezultati se ujemajo z rezultati omenjenih študij. Vloga IL-6 in IL-8 v patogenezi PDR ni popolnoma pojasnjena. IL-6 <italic>in vitro</italic> lahko vpliva na obliko endotelnih celic in s tem na krvno-mrežnično pregrado (<xref ref-type="bibr" rid="b25">25</xref>). IL-8 deluje kemoatraktivno, aktivira nevtrofilce in limfocite T ter deluje tudi angiogeno. Ugotovljeno je bilo, da njegova raven v steklovini korelira z aktivnostjo PDR (<xref ref-type="bibr" rid="b11">11</xref>). Samo porušenje krvno-mrežnične pregrade najverjetneje ni edini in zadosten razlog za višjo raven IL-6 in IL-8 v steklovini. Bolj verjetno je, da oba citokina tvorijo tudi celice, prisotne v steklovini bolnikov s PDR (makrofagi, monociti, celice glija, celice retinalnega pigmentnega epitela).</p>
         <p>VEGF je proangiogeni citokin, ki je ključnega pomena za razvoj neovaskularizacij, pomembno pa vpliva tudi na krvno-mrežnično pregrado. Številne študije so dokazale višjo raven VEGF pri bolnikih s PDR (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b8">8</xref>-<xref ref-type="bibr" rid="b11">11</xref>) in korelacijo VEGF z aktivnostjo bolezni (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b10">10</xref>,<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b13">13</xref>). Tudi v naši raziskavi smo ugotovili višjo raven VEGF v steklovini bolnikov s PDR tako v primerjavi s serumom kot v primerjavi s steklovino kontrolne skupine. Bolniki z aktivno PDR so imeli višjo raven VEGF v steklovini kot bolniki z neaktivno PDR, vendar razlike niso bile statistično pomembne.</p>
         <p>IL-1β je provnetni citokin, za katerega je bilo v študijah na živalskih modelih ugotovljeno, da igra pomembno vlogo pri razvoju DR. Ker ima kratek razpolovni čas in ker nastaja pretežno v tkivu, je višjo raven v steklovini bolnikov s sladkorno boleznijo v primerjavi s kontrolno skupino dokazalo le malo študij (<xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b26">26</xref>). V študiji, ki jo je opravil Yoshimura s sod., IL-1β v steklovini bolnikov s PDR niso dokazali, ker so bile koncentracije pod zaznavno mejo metode, ki so jo uporabili (<xref ref-type="bibr" rid="b6">6</xref>). Raven IL-1β v steklovini se v naši raziskavi ni pomembno razlikovala med skupino bolnikov s PDR in kontrolno skupino.</p>
         <p>TNF-α je provnetni citokin, ki je vključen v patogenezo številnih kroničnih vnetnih bolezni. Pri bolnikih s sladkorno boleznijo so ugotovili višjo raven TNF-α v serumu v primerjavi s kontrolno skupino ter močno korelacijo med ravnijo TNF-α v serumu in napredovalostjo DR (<xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b21">21</xref>). V študiji, ki jo je opravil Yoshimura s sod. (<xref ref-type="bibr" rid="b6">6</xref>), je bila raven TNF-α v steklovini bolnikov s PDR nezaznavna, v naši raziskavi pa je bila v steklovini bolnikov s PDR sicer višja kot v serumu, vendar se ni pomembno razlikovala od ravni v steklovini bolnikov kontrolne skupine. Tudi TNF-α ima podobno kot IL-1β kratek razpolovni čas, kar lahko daje lažno negativne rezultate.</p>
         <p>Ravni IL-12, IL-10 ter MIP-1α in MIP-1β so bile v naši raziskavi v steklovini pomembno nižje kot v serumu.</p>
         <p>IL-12 je provnetni citokin z antiangiogenim delovanjem (<xref ref-type="bibr" rid="b27">27</xref>). Študij, v katerih so preučevali IL-12 pri ljudeh s sladkorno boleznijo, je zelo malo. Pri otrocih s sladkorno boleznijo tipa 1 in DR so ugotovili pomembno nižjo raven IL-12 v serumu v primerjavi s kontrolno skupino (<xref ref-type="bibr" rid="b27">27</xref>). Z našo raziskavo smo ugotovili pomembno nižjo raven IL-12 v steklovini bolnikov s PDR v primerjavi s serumom. Raven IL-12 je bila v steklovini bolnikov s PDR tudi pomembno nižja v primerjavi s kontrolno skupino, čeprav so vrednosti precej variirale.</p>
         <p>O možni vlogi protivnetnih citokinov v patogenezi PDR je malo znanega. IL-10 je protivnetni citokin, ki ustavi makrofage in zavira izražanje VEGF. Mao s sod. je ugotovil višjo raven IL-10 v steklovini bolnikov s PDR (<xref ref-type="bibr" rid="b28">28</xref>), kar naj bi bilo v skladu z zaščitno vlogo IL-10 v vnetnem okolju. Nasprotno pa Hernandez in sod. niso ugotovili višje ravni IL-10 v steklovini bolnikov s PDR, iz česar so sklepali, da višje ravni provnetnih citokinov ne izzovejo tudi povišanja ravni citokinov z nasprotnim učinkom (<xref ref-type="bibr" rid="b29">29</xref>). Podobno tudi Zhou s sod. ni našel pomembne razlike med ravnijo IL-10 v steklovini bolnikov s PDR in ravnijo IL-10 v steklovini kontrolne skupine (<xref ref-type="bibr" rid="b10">10</xref>). Naši rezultati so v skladu z zaključki Hernandeza s sod. in Zhouja s sod., saj je bila raven IL-10 v steklovini naših bolnikov s PDR nižja kot raven v steklovini kontrolne skupine.</p>
         <p>MIP-1α in MIP-1β tvorijo makrofagi, delujeta kemotaktično, pomembna pa sta tudi v patogenezi neovaskularizacije mrežnice (<xref ref-type="bibr" rid="b30">30</xref>). Polimorfonuklearne celice, aktivirane z MIP-1α in MIP-1β, sproščajo citokine, kot so IL-1β, IL-6 in TNF-α. V študiji, ki jo je opravil Maier s sod., niso bile zaznavne ravni MIP-1α in MIP-1β v vzorcih steklovine tako v skupini bolnikov s PDR kot v kontrolni skupini, prav tako Capeans s sod. ni dokazala prisotnosti MIP-1α in MIP-1β v vzorcih steklovine skupine bolnikov s PDR in kontrolne skupine (<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b30">30</xref>). Capeans s sod. je na podlagi rezultatov svoje študije sklepala, da MIP-1α in MIP-1β verjetno nista vpletena v patogenezo PDR. Yoshimura in sod. so dokazali MIP-1β le v steklovini nekaterih bolnikov s PDR, raven MIP-1α pa je bila nižja od minimalne zaznavne koncentracije (<xref ref-type="bibr" rid="b6">6</xref>). V naši študiji je bila raven MIP-1α nad minimalno zaznavno mejo v 21 od 37 vzorcev steklovine bolnikov s PDR (56,7 %) ter v vseh vzorcih steklovine kontrolne skupine (100 %), razlike v ravni so bile statistično pomembno različne, variabilnost pa je bila v skupini bolnikov s PDR zelo velika. Raven MIP-1β je bila nižja od minimalne zaznavne koncentracije le v dveh vzorcih steklovine kontrolne skupine, v vseh vzorcih steklovine bolnikov s PDR pa smo dokazali prisotnost MIP-1β. Razlike med skupinama niso bile statistično pomembne. Med skupino bolnikov z aktivno obliko PDR in skupino bolnikov z neaktivno obliko PDR ni bilo pomembne razlike v ravni MIP-1α in MIP-1β. Glede na naše rezultate lahko pritrdimo sklepu Capeans s sod., da MIP-1α in MIP-1β verjetno nimata pomembne vloge v patogenezi DR. Statistično pomembno razliko med skupino bolnikov s PDR in kontrolno skupino, ki smo jo ugotovili glede na raven MIP-1α v steklovini, lahko pripišemo večji variabilnosti ravni v posameznih vzorcih (razpon 0–82,83 pg/ml pri bolnikih s PDR v primerjavi z razponom 9,67–47,34 pg/ml pri kontrolni skupini). To pa posredno prav tako lahko kaže na verjetno manjši pomen MIP-1α v patogenezi DR.</p>
      </sec>
      <sec id="s5" sec-type="Zaključek">
         <label>5</label>
         <title>Zaključek</title>
         <p>Vnetje v očesu je povezano s spremembami, ki nastanejo v sklopu diabetične retinopatije. Z našo raziskavo smo pri bolnikih s PDR dokazali pomembne razlike v ravneh citokinov med steklovino in serumom. Višja raven MCP-1, VEGF, IL-6 in IL-8 ter nižja raven MIP-1α, IL-10 in IL-12 v steklovini bolnikov s PDR v primerjavi s kontrolno skupino dodatno potrjuje pomen lokalnega vnetja v očesu pri diabetični retinopatiji. Višje ravni MCP-1, VEGF, IL-6 in IL-8 v steklovini nakazujejo aktivnost PDR. Boljše poznavanje patogenetskih mehanizmov in lokalnega vnetnega dogajanja v očesu lahko prispeva k razvoju učinkovitejših načinov zdravljenja.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fong</surname>
                     <given-names>DS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Aiello</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gardner</surname>
                     <given-names>TW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>King</surname>
                     <given-names>GL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blankenship</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cavallerano</surname>
                     <given-names>JD</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>American Diabetes Association</collab>
                    </person-group>. 
                    <article-title>Retinopathy in diabetes</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2004</year>
                    <month>Jan</month>;
                    <volume>27</volume>
                    <supplement>Suppl 1</supplement>:
                    <fpage>S84</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/diacare.27.2007.S84</pub-id>
                    <pub-id pub-id-type="pmid">14693935</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Tang</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kern</surname>
                     <given-names>TS</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Inflammation in diabetic retinopathy</article-title>. 
                    <source>Prog Retin Eye Res</source>. 
                    <year>2011</year>
                    <month>Sep</month>;
                    <volume>30</volume>(
                    <issue>5</issue>):
                    <fpage>343</fpage>–
                    <lpage>58</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.preteyeres.2011.05.002</pub-id>
                    <pub-id pub-id-type="pmid">21635964</pub-id>
                    <issn>1350-9462</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <label>3. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kaur</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Foulds</surname>
                     <given-names>WS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ling</surname>
                     <given-names>EA</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management</article-title>. 
                    <source>Prog Retin Eye Res</source>. 
                    <year>2008</year>
                    <month>Nov</month>;
                    <volume>27</volume>(
                    <issue>6</issue>):
                    <fpage>622</fpage>–
                    <lpage>47</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.preteyeres.2008.09.003</pub-id>
                    <pub-id pub-id-type="pmid">18940262</pub-id>
                    <issn>1350-9462</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ishizaki</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Takai</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ueki</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maeno</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maruichi</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sugiyama</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy</article-title>. 
                    <source>Am J Ophthalmol</source>. 
                    <year>2006</year>
                    <month>Jan</month>;
                    <volume>141</volume>(
                    <issue>1</issue>):
                    <fpage>129</fpage>–
                    <lpage>34</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ajo.2005.08.066</pub-id>
                    <pub-id pub-id-type="pmid">16386986</pub-id>
                    <issn>0002-9394</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Van den Steen</surname>
                     <given-names>PE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Proost</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wuyts</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Van Damme</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Opdenakker</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact</article-title>. 
                    <source>Blood</source>. 
                    <year>2000</year>
                    <month>Oct</month>;
                    <volume>96</volume>(
                    <issue>8</issue>):
                    <fpage>2673</fpage>–
                    <lpage>81</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood.V96.8.2673</pub-id>
                    <pub-id pub-id-type="pmid">11023497</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Yoshimura</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sonoda</surname>
                     <given-names>KH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sugahara</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mochizuki</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Enaida</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Oshima</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases</article-title>. 
                    <source>PLoS One</source>. 
                    <year>2009</year>
                    <month>Dec</month>;
                    <volume>4</volume>(
                    <issue>12</issue>):
                    <fpage>e8158</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0008158</pub-id>
                    <pub-id pub-id-type="pmid">19997642</pub-id>
                    <issn>1932-6203</issn>
                </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7. </label>
            <mixed-citation publication-type="book">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Chan</surname>
                     <given-names>CC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Smith</surname>
                     <given-names>WM</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>Inflammatory Response and Mediators in Retinal Injury</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Ryan</surname>
                     <given-names>SJ</given-names>
                  </name>, 
                        <role>editor</role>
                    </person-group>. 
                    <source>Retina</source>. 
                    <edition>5th ed</edition>.
                    <publisher-loc>Philadelphia</publisher-loc>: 
                    <publisher-name>W.B. Saunders</publisher-name>; 
                    <year>2013</year>. pp. 
                    <fpage>553</fpage>–
                    <lpage>61</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/B978-1-4557-0737-9.00025-4</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Abu El-Asrar</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Struyf</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kangave</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geboes</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Van Damme</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy</article-title>. 
                    <source>Eur Cytokine Netw</source>. 
                    <year>2006</year>
                    <month>Sep</month>;
                    <volume>17</volume>(
                    <issue>3</issue>):
                    <fpage>155</fpage>–
                    <lpage>65</lpage>.
                    <pub-id pub-id-type="pmid">17194635</pub-id>
                    <issn>1148-5493</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <label>9. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Abu El-Asrar</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nawaz</surname>
                     <given-names>MI</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kangave</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mairaj Siddiquei</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geboes</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy</article-title>. 
                    <source>J Diabetes Res</source>. 
                    <year>2013</year>;
                    <volume>2013</volume>:
                    <fpage>539658</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2013/539658</pub-id>
                    <pub-id pub-id-type="pmid">23671874</pub-id>
                    <issn>2314-6745</issn>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zhou</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Xia</surname>
                     <given-names>X</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy</article-title>. 
                    <source>Curr Eye Res</source>. 
                    <year>2012</year>
                    <month>May</month>;
                    <volume>37</volume>(
                    <issue>5</issue>):
                    <fpage>416</fpage>–
                    <lpage>20</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/02713683.2012.661114</pub-id>
                    <pub-id pub-id-type="pmid">22409294</pub-id>
                    <issn>0271-3683</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Aiello</surname>
                     <given-names>LP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Avery</surname>
                     <given-names>RL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Arrigg</surname>
                     <given-names>PG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Keyt</surname>
                     <given-names>BA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jampel</surname>
                     <given-names>HD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shah</surname>
                     <given-names>ST</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>1994</year>
                    <month>Dec</month>;
                    <volume>331</volume>(
                    <issue>22</issue>):
                    <fpage>1480</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJM199412013312203</pub-id>
                    <pub-id pub-id-type="pmid">7526212</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wakabayashi</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Usui</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Okunuki</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kezuka</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Takeuchi</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goto</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy</article-title>. 
                    <source>Retina</source>. 
                    <year>2010</year>
                    <month>Feb</month>;
                    <volume>30</volume>(
                    <issue>2</issue>):
                    <fpage>339</fpage>–
                    <lpage>44</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/IAE.0b013e3181bd2f44</pub-id>
                    <pub-id pub-id-type="pmid">20142713</pub-id>
                    <issn>0275-004X</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>El-Asrar</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nawaz</surname>
                     <given-names>MI</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kangave</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geboes</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ola</surname>
                     <given-names>MS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ahmad</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy</article-title>. 
                    <source>Mol Vis</source>. 
                    <year>2011</year>;
                    <volume>17</volume>:
                    <fpage>1829</fpage>–
                    <lpage>38</lpage>.
                    <pub-id pub-id-type="pmid">21850157</pub-id>
                    <issn>1090-0535</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14.  </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Capeans</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>De Rojas</surname>
                     <given-names>MV</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lojo</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Salorio</surname>
                     <given-names>MS</given-names>
                  </name>
                    </person-group>. 
                    <article-title>C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy</article-title>. 
                    <source>Retina</source>. 
                    <year>1998</year>;
                    <volume>18</volume>(
                    <issue>6</issue>):
                    <fpage>546</fpage>–
                    <lpage>50</lpage>.
                    <pub-id pub-id-type="pmid">9869464</pub-id>
                    <issn>0275-004X</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15.  </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Abu el Asrar</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maimone</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morse</surname>
                     <given-names>PH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gregory</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reder</surname>
                     <given-names>AT</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cytokines in the vitreous of patients with proliferative diabetic retinopathy</article-title>. 
                    <source>Am J Ophthalmol</source>. 
                    <year>1992</year>
                    <month>Dec</month>;
                    <volume>114</volume>(
                    <issue>6</issue>):
                    <fpage>731</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0002-9394(14)74052-8</pub-id>
                    <pub-id pub-id-type="pmid">1463043</pub-id>
                    <issn>0002-9394</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16.  </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Petrovič</surname>
                     <given-names>MG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Korošec</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Košnik</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hawlina</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Association of preoperative vitreous IL-8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy</article-title>. 
                    <source>Acta Ophthalmol</source>. 
                    <year>2010</year>
                    <month>Dec</month>;
                    <volume>88</volume>(
                    <issue>8</issue>):
                    <fpage>e311</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1755-3768.2010.02030.x</pub-id>
                    <pub-id pub-id-type="pmid">21073666</pub-id>
                    <issn>1755-375X</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Petrovic</surname>
                     <given-names>MG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Korošec</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Košnik</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hawlina</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy</article-title>. 
                    <source>Am J Ophthalmol</source>. 
                    <year>2007</year>
                    <month>Jan</month>;
                    <volume>143</volume>(
                    <issue>1</issue>):
                    <fpage>175</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ajo.2006.07.032</pub-id>
                    <pub-id pub-id-type="pmid">17188064</pub-id>
                    <issn>0002-9394</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Demircan</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Safran</surname>
                     <given-names>BG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Soylu</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ozcan</surname>
                     <given-names>AA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sizmaz</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy</article-title>. 
                    <source>Eye (Lond)</source>. 
                    <year>2006</year>
                    <month>Dec</month>;
                    <volume>20</volume>(
                    <issue>12</issue>):
                    <fpage>1366</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.eye.6702138</pub-id>
                    <pub-id pub-id-type="pmid">16284605</pub-id>
                    <issn>0950-222X</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wu</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yu</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous</article-title>. 
                    <source>BioMed Res Int</source>. 
                    <year>2014</year>;
                    <volume>2014</volume>:
                    <fpage>486386</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2014/486386</pub-id>
                    <pub-id pub-id-type="pmid">25401103</pub-id>
                    <issn>2314-6133</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Goldberg</surname>
                     <given-names>RB</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications</article-title>. 
                    <source>J Clin Endocrinol Metab</source>. 
                    <year>2009</year>
                    <month>Sep</month>;
                    <volume>94</volume>(
                    <issue>9</issue>):
                    <fpage>3171</fpage>–
                    <lpage>82</lpage>. 
                    <pub-id pub-id-type="doi">10.1210/jc.2008-2534</pub-id>
                    <pub-id pub-id-type="pmid">19509100</pub-id>
                    <issn>0021-972X</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <label>21.  </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hang</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yuan</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yang</surname>
                     <given-names>Q</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yuan</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Liu</surname>
                     <given-names>Q</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy</article-title>. 
                    <source>Mol Vis</source>. 
                    <year>2014</year>
                    <month>Aug</month>;
                    <volume>20</volume>:
                    <fpage>1137</fpage>–
                    <lpage>45</lpage>.
                    <pub-id pub-id-type="pmid">25253986</pub-id>
                    <issn>1090-0535</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ozturk</surname>
                     <given-names>BT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bozkurt</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kerimoglu</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Okka</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kamis</surname>
                     <given-names>U</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gunduz</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness</article-title>. 
                    <source>Mol Vis</source>. 
                    <year>2009</year>
                    <month>Sep</month>;
                    <volume>15</volume>:
                    <fpage>1906</fpage>–
                    <lpage>14</lpage>.
                    <pub-id pub-id-type="pmid">19784389</pub-id>
                    <issn>1090-0535</issn>
                </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Doganay</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Evereklioglu</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Er</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Türköz</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sevinç</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mehmet</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus</article-title>. 
                    <source>Eye (Lond)</source>. 
                    <year>2002</year>
                    <month>Mar</month>;
                    <volume>16</volume>(
                    <issue>2</issue>):
                    <fpage>163</fpage>–
                    <lpage>70</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj/eye/6700095</pub-id>
                    <pub-id pub-id-type="pmid">11988817</pub-id>
                    <issn>0950-222X</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Taghavi</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hassanshahi</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kounis</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Koniari</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Khorramdelazad</surname>
                     <given-names>H</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Monocyte Chemoattractant protein-1 (MCP-1/CCL2) in Diabetic Retinopathy: Latest Evidence and Clinical Considerations</article-title>. 
                    <source>J Cell Commun Signal</source>. 
                    <year>2019</year>
                    <month>Jan</month>;
                    <volume>13</volume>(
                    <issue>4</issue>): 
                    <fpage>451</fpage>–
                    <lpage>62</lpage>
                    <pub-id pub-id-type="doi">10.1007/s12079-018-00500-8</pub-id>
                    <pub-id pub-id-type="pmid">30607767</pub-id>
                    <issn>1873-9601</issn>
                </mixed-citation>
         </ref>
         <ref id="b25">
            <label>25. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Simó-Servat</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hernández</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Simó</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy</article-title>. 
                    <source>Mediators Inflamm</source>. 
                    <year>2012</year>;
                    <volume>2012</volume>:
                    <fpage>872978</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2012/872978</pub-id>
                    <pub-id pub-id-type="pmid">23028204</pub-id>
                    <issn>0962-9351</issn>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <label>26. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Tsai</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kuehn</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tsiampalis</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vu</surname>
                     <given-names>MK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kakkassery</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stute</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients</article-title>. 
                    <source>PLoS One</source>. 
                    <year>2018</year>
                    <month>Mar</month>;
                    <volume>13</volume>(
                    <issue>3</issue>):
                    <fpage>e0194603</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0194603</pub-id>
                    <pub-id pub-id-type="pmid">29584759</pub-id>
                    <issn>1932-6203</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <label>27. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zorena</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Raczyńska</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Raczyńska</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Biomarkers in diabetic retinopathy and the therapeutic implications</article-title>. 
                    <source>Mediators Inflamm</source>. 
                    <year>2013</year> 
                    <month>Nov</month>;
                    <volume>2013</volume>:
                    <fpage>193604</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2013/193604</pub-id>
                    <pub-id pub-id-type="pmid">24311895</pub-id>
                    <issn>0962-9351</issn>
                </mixed-citation>
         </ref>
         <ref id="b28">
            <label>28. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Mao</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yan</surname>
                     <given-names>H</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Roles of elevated intravitreal IL-1β and IL-10 levels in proliferative diabetic retinopathy</article-title>. 
                    <source>Indian J Ophthalmol</source>. 
                    <year>2014</year>
                    <month>Jun</month>;
                    <volume>62</volume>(
                    <issue>6</issue>):
                    <fpage>699</fpage>–
                    <lpage>701</lpage>. 
                    <pub-id pub-id-type="doi">10.4103/0301-4738.136220</pub-id>
                    <pub-id pub-id-type="pmid">25005199</pub-id>
                    <issn>0301-4738</issn>
                </mixed-citation>
         </ref>
         <ref id="b29">
            <label>29. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hernández</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Segura</surname>
                     <given-names>RM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fonollosa</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carrasco</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Francisco</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Simó</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy</article-title>. 
                    <source>Diabet Med</source>. 
                    <year>2005</year>
                    <month>Jun</month>;
                    <volume>22</volume>(
                    <issue>6</issue>):
                    <fpage>719</fpage>–
                    <lpage>22</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1464-5491.2005.01538.x</pub-id>
                    <pub-id pub-id-type="pmid">15910622</pub-id>
                    <issn>0742-3071</issn>
                </mixed-citation>
         </ref>
         <ref id="b30">
            <label>30. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Maier</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weger</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Haller-Schober</surname>
                     <given-names>EM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>El-Shabrawi</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wedrich</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Theisl</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients</article-title>. 
                    <source>Mol Vis</source>. 
                    <year>2008</year>
                    <month>Mar</month>;
                    <volume>14</volume>:
                    <fpage>637</fpage>–
                    <lpage>43</lpage>.
                    <pub-id pub-id-type="pmid">18385799</pub-id>
                    <issn>1090-0535</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
